Angiogenic Factor Expression During Fractionated Irradiation
Status:
Unknown status
Trial end date:
2021-05-01
Target enrollment:
Participant gender:
Summary
The main question of this study is if and when VEGF (vascular endothelial growth factor)
expression in the tumor is upregulated during chemoradiation and if bevacizumab inhibits
subsequent vessel growth in the tumor.
- Therefore the first aim of this study is to identify the time point of induction of VEGF
in the tumor tissue of esophagus carcinoma during chemoradiation (after 1,2,3 or 4 weeks
of chemoradiation).
- If we identify increased expression of VEGF at a certain time point, our second aim is
to determine if we can inhibit the subsequent tumor vessel growth by administration of
bevacizumab.
Phase:
Early Phase 1
Details
Lead Sponsor:
VU University Medical Center
Collaborators:
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) Noordwest Ziekenhuisgroep